Entasis Therapeutics Holdings Inc. (ETTX) NASDAQ
$2.19 - (-)
Market Cap: -
As of 07/08/22 12:00 AM EDT. Market closed.
Entasis Therapeutics Holdings Inc. (ETTX)
NASDAQ
$2.19
- (-)
Market Cap: -
As of 07/08/22 12:00 AM EDT. Market closed.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), ... read more
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Innoviva, Inc. | 10% Owner | Jul 11, 2022 | Buy | $2.20 | 7,598,814 | 16,717,391 | 29,270,476 | Jul 13, 2022, 09:27 PM |
Innoviva, Inc. | 10% Owner | Jul 08, 2022 | Buy | $2.20 | 11,671,662 | 25,677,657 | 21,671,662 | Jul 13, 2022, 09:27 PM |
Tommasi Ruben | Chief Scientific Officer | Jul 07, 2022 | Option Exercise | $2.20 | 39,596 | 87,111 | 0 | Jul 11, 2022, 04:09 PM |
Ronsheim Matthew | Chief of Pharma Sciences & MFG | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:09 PM |
Perros Manoussos | President and CEO | Jul 07, 2022 | Option Exercise | $2.20 | 56,072 | 123,358 | 0 | Jul 11, 2022, 04:08 PM |
Mueller John Patrick | Chief Development Officer | Jul 07, 2022 | Option Exercise | $2.20 | 17,092 | 37,602 | 0 | Jul 11, 2022, 04:07 PM |
Meek David D. | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:07 PM |
Meek David D. | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:07 PM |
Mayer Howard | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:06 PM |
Mayer Howard | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:06 PM |
Keiley Elizabeth M | General Counsel | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:06 PM |
HASTINGS DAVID C | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:05 PM |
HASTINGS DAVID C | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:05 PM |
Berger Heather A. | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:04 PM |
Berger Heather A. | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:04 PM |
Altarac David | Chief Medical Officer | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:03 PM |
Ronsheim Matthew | Chief, Pharma Sciences & MFG. | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:05 PM |
Keiley Elizabeth M | General Counsel | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:04 PM |
Altarac David | Chief Medical Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:04 PM |
Mueller John Patrick | Chief Development Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,907 | 11,487 | 42,092 | Nov 03, 2021, 04:03 PM |
Perros Manoussos | President and CEO | Nov 02, 2021 | Option Exercise | $2.94 | 11,704 | 34,410 | 135,822 | Nov 03, 2021, 04:03 PM |
Gutch Michael | CFO and Chief Business Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:02 PM |
Tommasi Ruben | Chief Scientific Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 64,596 | Nov 03, 2021, 04:02 PM |
Perros Manoussos | See Remarks | Oct 19, 2021 | Sale | $3.19 | 11,974 | 38,197 | 147,526 | Oct 20, 2021, 04:14 PM |
Mueller John Patrick | Chief Development Officer | Oct 19, 2021 | Sale | $3.19 | 4,001 | 12,763 | 45,999 | Oct 20, 2021, 04:10 PM |
Gutch Michael | See Remarks | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:09 PM |
Tommasi Ruben | Chief Scientific Officer | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 68,265 | Oct 20, 2021, 04:08 PM |
Keiley Elizabeth M | General Counsel | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:08 PM |
Altarac David | Chief Medical Officer | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:06 PM |
Ronsheim Matthew | See Remarks | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:05 PM |
Innoviva, Inc. | 10% Owner | Sep 01, 2020 | Buy | $2.67 | 4,672,897 | 12,499,999 | 18,672,897 | Sep 01, 2020, 05:31 PM |
Innoviva, Inc. | 10% Owner | Jun 11, 2020 | Buy | $2.50 | 12,677,490 | 31,693,725 | 14,000,000 | Jun 12, 2020, 05:34 PM |
Frazier Life Sciences VIII, L.P. | 10% Owner | Jan 09, 2020 | Sale | $5.00 | 50,000 | 250,010 | 1,299,953 | Jan 13, 2020, 10:47 AM |
Tommasi Ruben | Chief Scientific Officer | Dec 21, 2018 | Option Exercise | $3.45 | 22,024 | 75,921 | 22,024 | Dec 26, 2018, 04:45 PM |
Topper James N | Director | Sep 28, 2018 | Buy | $15.00 | 375,887 | 5,638,305 | 1,349,953 | Oct 02, 2018, 09:42 PM |
Sofinnova Venture Partners IX, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 337,724 | 5,065,860 | 1,180,178 | Oct 02, 2018, 09:41 PM |
Preston Heather | Director | Sep 28, 2018 | Buy | $15.00 | 337,724 | 5,065,860 | 1,180,178 | Oct 02, 2018, 09:40 PM |
Pivotal bioVenture Partners Fund I, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 337,724 | 5,065,860 | 1,180,178 | Oct 02, 2018, 09:39 PM |
GALAKATOS NICHOLAS | Director | Sep 28, 2018 | Buy | $15.00 | 453,395 | 6,800,925 | 1,623,405 | Oct 02, 2018, 09:38 PM |
Frazier Life Sciences VIII, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 375,887 | 5,638,305 | 1,349,953 | Oct 02, 2018, 09:38 PM |
Clarus Lifesciences III, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 453,395 | 6,800,925 | 1,623,405 | Oct 02, 2018, 09:36 PM |
ASTRAZENECA PLC | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 246,666 | 3,699,990 | 2,164,855 | Oct 02, 2018, 09:35 PM |
TPG Group Holdings (SBS) Advisors, Inc. | Former 10% Owner | Sep 28, 2018 | Buy | $15.00 | 262,539 | 3,938,085 | 1,020,748 | Oct 02, 2018, 04:46 PM |
Novo Holdings A/S | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 1,089,835 | 16,347,525 | 2,181,843 | Oct 01, 2018, 04:36 PM |
Owner | Relationship | Date | Value($) |
Innoviva, Inc. | 10% Owner | 07/11/2022 | 16,717,391 |
Innoviva, Inc. | 10% Owner | 07/08/2022 | 25,677,657 |
Tommasi Ruben | Chief Scientific Officer | 07/07/2022 | 87,111 |
Ronsheim Matthew | Chief of Pharma Sciences & MFG | 07/07/2022 | 38,658 |
Perros Manoussos | President and CEO | 07/07/2022 | 123,358 |
Mueller John Patrick | Chief Development Officer | 07/07/2022 | 37,602 |
Meek David D. | Director | 07/11/2022 | 60,500 |
Meek David D. | Director | 07/07/2022 | 48,400 |
Mayer Howard | Director | 07/11/2022 | 60,500 |
Mayer Howard | Director | 07/07/2022 | 48,400 |
Keiley Elizabeth M | General Counsel | 07/07/2022 | 38,658 |
HASTINGS DAVID C | Director | 07/11/2022 | 60,500 |
HASTINGS DAVID C | Director | 07/07/2022 | 48,400 |
Berger Heather A. | Director | 07/11/2022 | 60,500 |
Berger Heather A. | Director | 07/07/2022 | 48,400 |
Altarac David | Chief Medical Officer | 07/07/2022 | 38,658 |
Ronsheim Matthew | Chief, Pharma Sciences & MFG. | 11/02/2021 | 10,787 |
Keiley Elizabeth M | General Counsel | 11/02/2021 | 10,787 |
Altarac David | Chief Medical Officer | 11/02/2021 | 10,787 |
Mueller John Patrick | Chief Development Officer | 11/02/2021 | 11,487 |
Perros Manoussos | President and CEO | 11/02/2021 | 34,410 |
Gutch Michael | CFO and Chief Business Officer | 11/02/2021 | 10,787 |
Tommasi Ruben | Chief Scientific Officer | 11/02/2021 | 10,787 |
Perros Manoussos | See Remarks | 10/19/2021 | 38,197 |
Mueller John Patrick | Chief Development Officer | 10/19/2021 | 12,763 |
Gutch Michael | See Remarks | 10/19/2021 | 11,991 |
Tommasi Ruben | Chief Scientific Officer | 10/19/2021 | 11,991 |
Keiley Elizabeth M | General Counsel | 10/19/2021 | 11,991 |
Altarac David | Chief Medical Officer | 10/19/2021 | 11,991 |
Ronsheim Matthew | See Remarks | 10/19/2021 | 11,991 |
Innoviva, Inc. | 10% Owner | 09/01/2020 | 12,499,999 |
Innoviva, Inc. | 10% Owner | 06/11/2020 | 31,693,725 |
Frazier Life Sciences VIII, L.P. | 10% Owner | 01/09/2020 | 250,010 |
Tommasi Ruben | Chief Scientific Officer | 12/21/2018 | 75,921 |
Topper James N | Director | 09/28/2018 | 5,638,305 |
Sofinnova Venture Partners IX, L.P. | 10% Owner | 09/28/2018 | 5,065,860 |
Preston Heather | Director | 09/28/2018 | 5,065,860 |
Pivotal bioVenture Partners Fund I, L.P. | 10% Owner | 09/28/2018 | 5,065,860 |
GALAKATOS NICHOLAS | Director | 09/28/2018 | 6,800,925 |
Frazier Life Sciences VIII, L.P. | 10% Owner | 09/28/2018 | 5,638,305 |
Clarus Lifesciences III, L.P. | 10% Owner | 09/28/2018 | 6,800,925 |
ASTRAZENECA PLC | 10% Owner | 09/28/2018 | 3,699,990 |
TPG Group Holdings (SBS) Advisors, Inc. | Former 10% Owner | 09/28/2018 | 3,938,085 |
Novo Holdings A/S | 10% Owner | 09/28/2018 | 16,347,525 |